CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

Market Cap	282.50B
Revenue (ttm)	94.73B
Net Income (ttm)	-18.00B
Shares Out	147.68M
EPS (ttm)	-128.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,024
Average Volume	319,616
Open	1,917.00
Previous Close	1,916.00
Day's Range	1,892.00 - 1,917.00
52-Week Range	1,590.00 - 3,345.00
Beta	0.77
RSI	48.60
Earnings Date	Nov 13, 2025

About CMG Pharmaceutical

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 223
• Stock Exchange: KOSDAQ
• Ticker Symbol: 058820

Financial Performance

In 2024, CMG Pharmaceutical's revenue was 99.10 billion, an increase of 5.53% compared to the previous year's 93.91 billion. Earnings were 2.69 billion, a decrease of -58.26%.